{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:29:46Z","timestamp":1794018586811,"version":"4.8.0"},"reference-count":48,"publisher":"American Association for Cancer Research (AACR)","issue":"1","funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["101136379"],"award-info":[{"award-number":["101136379"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["853988"],"award-info":[{"award-number":["853988"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["03ZU111MB"],"award-info":[{"award-number":["03ZU111MB"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001655","name":"Deutscher Akademischer Austauschdienst","doi-asserted-by":"publisher","award":["57616814"],"award-info":[{"award-number":["57616814"]}],"id":[{"id":"10.13039\/501100001655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SPPy bone"],"award-info":[{"award-number":["SPPy bone"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018857","name":"International Myeloma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Establishing a strategy for sequencing of T cell\u2013redirecting therapies for relapsed\/refractory multiple myeloma (RRMM) is a pressing clinical need. We longitudinally tracked the clinical and immunologic impact of bispecific T cell\u2013engaging antibodies (BsAb) as bridging therapy (BT) to subsequent B-cell maturation antigen\u2013directed chimeric antigen receptor T (CAR-T) cell therapies in 52 patients with RRMM. BsAbs were a potent and safe option for BT, achieving the highest overall response rate (100%) to BT compared with chemotherapy, anti-CD38, or anti-SLAMF7 antibody\u2013based regimens (46%). We observed early CD4+CAR+ and delayed CD8+CAR+ T-cell expansion in patients receiving BsAbs as BT. In vitro cytotoxicity of CAR-T cells was comparable among BT options. Single-cell analyses revealed increased clonality in the CD4+ and CD8+ T-cell compartments in patients with previous exposure to BsAbs at leukapheresis and on day 30 after CAR-T cell infusion. This study demonstrates the feasibility and efficacy of BT with BsAbs for CAR-T cell therapy in RRMM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>CAR-T cell therapy and BsAbs have revolutionized treatment of triple-class refractory multiple myeloma; however, optimal sequencing is unknown. We demonstrate that BT with BsAb before B-cell maturation antigen\u2013directed CAR-T cell therapy is safe and effective, which might have implications for other hematologic malignancies as well.<\/jats:p>\n                    <jats:p>See related commentary by Bal and Costa, p. 10<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-24-0118","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T10:39:43Z","timestamp":1729679983000},"page":"38-54","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed\/Refractory Multiple Myeloma"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4014-6030","authenticated-orcid":false,"given":"David","family":"Fandrei","sequence":"first","affiliation":[{"name":"1Department of Hematology, Hemostaseology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany."},{"name":"2Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6850-4796","authenticated-orcid":false,"given":"Sabine","family":"Seiffert","sequence":"additional","affiliation":[{"name":"3Department of Clinical Immunology, University Hospital Leipzig, Leipzig, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6247-9289","authenticated-orcid":false,"given":"Michael","family":"Rade","sequence":"additional","affiliation":[{"name":"2Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2648-7316","authenticated-orcid":false,"given":"Susanne","family":"Rieprecht","sequence":"additional","affiliation":[{"name":"4Pharmacy, University Hospital Leipzig, Leipzig, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0891-1744","authenticated-orcid":false,"given":"Nico","family":"Gagelmann","sequence":"additional","affiliation":[{"name":"5Department of Bone Marrow Transplantation, University Hospital Hamburg-Eppendorf UKE, Hamburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8463-5179","authenticated-orcid":false,"given":"Patrick","family":"Born","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hemostaseology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2053-3857","authenticated-orcid":false,"given":"Thomas","family":"Wiemers","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hemostaseology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6045-3349","authenticated-orcid":false,"given":"Heike","family":"Weidner","sequence":"additional","affiliation":[{"name":"6Bone Lab Dresden, Universit\u00e4tsklinikum Carl Gustav Carus, TU Dresden, Dresden, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0520-8391","authenticated-orcid":false,"given":"Markus","family":"Kreuz","sequence":"additional","affiliation":[{"name":"2Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7915-640X","authenticated-orcid":false,"given":"Tamara","family":"Schassberger","sequence":"additional","affiliation":[{"name":"3Department of Clinical Immunology, University Hospital Leipzig, Leipzig, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3431-5611","authenticated-orcid":false,"given":"Jannik","family":"Ko\u00dfmann","sequence":"additional","affiliation":[{"name":"3Department of Clinical Immunology, University Hospital Leipzig, Leipzig, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4301-5059","authenticated-orcid":false,"given":"Marlene","family":"Mangold","sequence":"additional","affiliation":[{"name":"3Department of Clinical Immunology, University Hospital Leipzig, Leipzig, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9542-3169","authenticated-orcid":false,"given":"Daniel","family":"F\u00fcrst","sequence":"additional","affiliation":[{"name":"7Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg-Hessen, Ulm, University Hospital Ulm, Ulm, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3619-2958","authenticated-orcid":false,"given":"Luise","family":"Fischer","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hemostaseology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2539-7849","authenticated-orcid":false,"given":"Ronny","family":"Baber","sequence":"additional","affiliation":[{"name":"8Institute of Laboratory Medicine, Clinical Chemistry, and Molecular Diagnostics, University Hospital Leipzig, Leipzig, Germany."},{"name":"9Leipzig Medical Biobank, Leipzig, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8884-3210","authenticated-orcid":false,"given":"Simone","family":"Heyn","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hemostaseology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5433-8750","authenticated-orcid":false,"given":"Song Yau","family":"Wang","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hemostaseology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0919-7730","authenticated-orcid":false,"given":"Enrica","family":"Bach","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hemostaseology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4261-2104","authenticated-orcid":false,"given":"Sandra","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hemostaseology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3920-7490","authenticated-orcid":false,"given":"Klaus H.","family":"Metzeler","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hemostaseology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7473-7476","authenticated-orcid":false,"given":"Marco","family":"Herling","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hemostaseology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2270-0804","authenticated-orcid":false,"given":"Madlen","family":"Jentzsch","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hemostaseology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8239-002X","authenticated-orcid":false,"given":"Georg-Nikolaus","family":"Franke","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hemostaseology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8159-9160","authenticated-orcid":false,"given":"Ulrike","family":"K\u00f6hl","sequence":"additional","affiliation":[{"name":"2Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany."},{"name":"3Department of Clinical Immunology, University Hospital Leipzig, Leipzig, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7221-4222","authenticated-orcid":false,"given":"Maik","family":"Friedrich","sequence":"additional","affiliation":[{"name":"3Department of Clinical Immunology, University Hospital Leipzig, Leipzig, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5682-044X","authenticated-orcid":false,"given":"Andreas","family":"Boldt","sequence":"additional","affiliation":[{"name":"3Department of Clinical Immunology, University Hospital Leipzig, Leipzig, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4452-4872","authenticated-orcid":false,"given":"Kristin","family":"Reiche","sequence":"additional","affiliation":[{"name":"2Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany."},{"name":"3Department of Clinical Immunology, University Hospital Leipzig, Leipzig, Germany."},{"name":"10Center for Scalable Data Analytics and Artificial Intelligence (ScaDS.AI), Dresden, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1863-3239","authenticated-orcid":false,"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hemostaseology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8398-285X","authenticated-orcid":false,"given":"Vladan","family":"Vucinic","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hemostaseology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2805-5973","authenticated-orcid":false,"given":"Maximilian","family":"Merz","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hemostaseology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"2026041310205906000_bib1","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"key":"2026041310205906000_bib2","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"2026041310205906000_bib3","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"2026041310205906000_bib4","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"2026041310205906000_bib5","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"2026041310205906000_bib6","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"2026041310205906000_bib7","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"2026041310205906000_bib8","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"2026041310205906000_bib9","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026041310205906000_bib10","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"2026041310205906000_bib11","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"2026041310205906000_bib12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/jha2.335","article-title":"Role of bridging therapy during chimeric antigen receptor T cell therapy","volume":"3","author":"Bhaskar","year":"2022","journal-title":"EJHaem"},{"key":"2026041310205906000_bib13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41408-024-00993-0","article-title":"Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium","volume":"14","author":"Afrough","year":"2024","journal-title":"Blood Cancer J"},{"key":"2026041310205906000_bib14","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1200\/JCO.23.02232","article-title":"Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma","volume":"42","author":"Gagelmann","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026041310205906000_bib15","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026041310205906000_bib16","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3389\/fimmu.2017.00194","article-title":"CD4 CTL, a cytotoxic subset of CD4+ T cells, their differentiation and function","volume":"8","author":"Takeuchi","year":"2017","journal-title":"Front Immunol"},{"key":"2026041310205906000_bib17","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/bloodadvances.2022007625","article-title":"Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed\/refractory multiple myeloma","volume":"7","author":"Girgis","year":"2023","journal-title":"Blood Adv"},{"key":"2026041310205906000_bib18","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41375-023-02129-y","article-title":"Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed\/refractory myeloma","volume":"38","author":"Fischer","year":"2024","journal-title":"Leukemia"},{"key":"2026041310205906000_bib19","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","article-title":"Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion","volume":"19","author":"Amini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"Suppl 1","key":"2026041310205906000_bib20","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1182\/blood-2023-187755","article-title":"Mechanisms of resistance and relapse with talquetamab in patients with relapsed\/refractory multiple myeloma from the phase 1\/2 MonumenTAL-1 study","volume":"142","author":"Vishwamitra","year":"2023","journal-title":"Blood"},{"key":"2026041310205906000_bib21","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1038\/s41375-021-01172-x","article-title":"Selective elimination of immunosuppressive T cells in patients with multiple myeloma","volume":"35","author":"Awwad","year":"2021","journal-title":"Leukemia"},{"key":"2026041310205906000_bib22","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41375-020-0855-4","article-title":"Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab","volume":"35","author":"Casneuf","year":"2021","journal-title":"Leukemia"},{"key":"2026041310205906000_bib23","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"key":"2026041310205906000_bib24","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1158\/1078-0432.CCR-23-3333","article-title":"T-cell characteristics impact response and resistance to T-cell\u2013redirecting bispecific antibodies in multiple myeloma","volume":"30","author":"Verkleij","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026041310205906000_bib25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ymthe.2021.10.004","article-title":"PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells","volume":"30","author":"Lee","year":"2022","journal-title":"Mol Ther"},{"key":"2026041310205906000_bib26","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/s43018-024-00763-8","article-title":"Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma","volume":"5","author":"Rade","year":"2024","journal-title":"Nat Cancer"},{"issue":"Suppl 1","key":"2026041310205906000_bib27","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood-2023-187242","article-title":"Updated results of talquetamab, a GPRC5D \u00d7 CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma with prior exposure to T-cell redirecting therapies: results of the phase 1\/2 MonumenTAL-1 study","volume":"142","author":"Jakubowiak","year":"2023","journal-title":"Blood"},{"key":"2026041310205906000_bib28","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1182\/bloodadvances.2023012066","article-title":"Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma","volume":"8","author":"Reyes","year":"2024","journal-title":"Blood Adv"},{"key":"2026041310205906000_bib29","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","article-title":"Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy","volume":"13","author":"Ferreri","year":"2023","journal-title":"Blood Cancer J"},{"key":"2026041310205906000_bib30","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1182\/blood.2022018905","article-title":"CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS","volume":"143","author":"Sakemura","year":"2024","journal-title":"Blood"},{"key":"2026041310205906000_bib31","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1158\/2643-3230.BCD-23-0212","article-title":"Understanding mechanisms of response to CAR T-cell therapy through single-cell sequencing: insights and challenges","volume":"5","author":"Haradhvala","year":"2024","journal-title":"Blood Cancer Discov"},{"key":"2026041310205906000_bib32","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.2023022499","article-title":"BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety and resistance mechanisms","volume":"143","author":"Lee","year":"2024","journal-title":"Blood"},{"issue":"Suppl 1","key":"2026041310205906000_bib33","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1182\/blood-2023-190517","article-title":"Immune and genome profiling of myeloma patients treated with sequential immunotherapies reveal differential non-overlapping mechanisms of resistance","volume":"142","author":"Lee","year":"2023","journal-title":"Blood"},{"key":"2026041310205906000_bib34","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"2026041310205906000_bib35","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1182\/blood-2023-187409","article-title":"Sequential T-cell engagement for myeloma (\u201cSTEM\u201d) trial: a phase 2 study of cevostamab consolidation following BCMA CAR T cell therapy","volume":"142","author":"Cohen","year":"2023","journal-title":"Blood"},{"key":"2026041310205906000_bib36","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026041310205906000_bib37","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026041310205906000_bib38","doi-asserted-by":"crossref","first-page":"658314","DOI":"10.3389\/fimmu.2021.658314","article-title":"Advanced flow cytometry assays for immune monitoring of CAR-T cell applications","volume":"12","author":"Blache","year":"2021","journal-title":"Front Immunol"},{"key":"2026041310205906000_bib39","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/cytob.21162","article-title":"Eight color immunophenotyping of T-B- and NK-cell subpopulations for characterization of chronic immunodeficiencies","volume":"86","author":"Boldt","year":"2014","journal-title":"Cytometry B Clin Cytom"},{"key":"2026041310205906000_bib40","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1182\/bloodadvances.2023009714","article-title":"Teclistamab impairs detection of BCMA CAR-T cells","volume":"7","author":"Glatte","year":"2023","journal-title":"Blood Adv"},{"key":"2026041310205906000_bib41","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.3390\/biomedicines12081641","article-title":"Evaluation of anti-CAR linker mAbs for CAR T monitoring after BiTEs\/bsAbs and CAR T-cell pretreatment","volume":"12","author":"Grahnert","year":"2024","journal-title":"Biomedicines"},{"key":"2026041310205906000_bib42","doi-asserted-by":"crossref","first-page":"979","DOI":"10.12688\/f1000research.73600.2","article-title":"Doublet identification in single-cell sequencing data using scDblFinder","volume":"10","author":"Germain","year":"2022","journal-title":"F1000Res"},{"key":"2026041310205906000_bib43","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","article-title":"Dictionary learning for integrative, multimodal and scalable single-cell analysis","volume":"42","author":"Hao","year":"2024","journal-title":"Nat Biotechnol"},{"key":"2026041310205906000_bib44","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","article-title":"Comprehensive integration of single-cell data","volume":"177","author":"Stuart","year":"2019","journal-title":"Cell"},{"key":"2026041310205906000_bib45","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"key":"2026041310205906000_bib46","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1038\/s41467-021-23324-4","article-title":"Interpretation of T cell states from single-cell transcriptomics data using reference atlases","volume":"12","author":"Andreatta","year":"2021","journal-title":"Nat Commun"},{"key":"2026041310205906000_bib47","doi-asserted-by":"crossref","first-page":"47","DOI":"10.12688\/f1000research.22139.1","article-title":"scRepertoire: an R-based toolkit for single-cell immune receptor analysis","volume":"9","author":"Borcherding","year":"2020","journal-title":"F1000Res"},{"key":"2026041310205906000_bib48","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1016\/j.csbj.2021.06.043","article-title":"UCell: robust and scalable single-cell gene signature scoring","volume":"19","author":"Andreatta","year":"2021","journal-title":"Comput Struct Biotechnol J"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-24-0118\/3511229\/bcd-24-0118.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-24-0118\/3525326\/bcd-24-0118.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/1\/38\/3530188\/bcd-24-0118.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/1\/38\/3530188\/bcd-24-0118.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:21:16Z","timestamp":1776090076000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/6\/1\/38\/750803\/Bispecific-Antibodies-as-Bridging-to-BCMA-CAR-T"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,10,23]]},"published-print":{"date-parts":[[2025,1,8]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-24-0118","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.c.7616209","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2643-3230.28159540","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32696538","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32696526","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.28159534","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.28159531","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32696544","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.28159543","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32696532","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.28159537","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32696520","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]}}}